Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Debt to Equity: 2016-2025

Historic Debt to Equity for Rhythm Pharmaceuticals (RYTM) over the last 1 years, with Sep 2025 value amounting to $0.73.

  • Rhythm Pharmaceuticals' Debt to Equity was N/A to $0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.73, marking a year-over-year change of. This contributed to the annual value of $5.05 for FY2024, which is 708.25% up from last year.
  • Rhythm Pharmaceuticals' Debt to Equity amounted to $0.73 in Q3 2025, which was up 107.94% from -$9.22 recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Debt to Equity peaked at $5.78 during Q1 2025, and registered a low of -$9.22 during Q2 2025.
  • In the last 3 years, Rhythm Pharmaceuticals' Debt to Equity had a median value of $0.73 in 2025 and averaged $0.59.
  • Data for Rhythm Pharmaceuticals' Debt to Equity shows a peak YoY spiked of 708.25% (in 2024) over the last 5 years.
  • Over the past 3 years, Rhythm Pharmaceuticals' Debt to Equity (Quarterly) stood at $0.63 in 2023, then surged by 708.25% to $5.05 in 2024, then reached $0.73 in 2025.
  • Its Debt to Equity stands at $0.73 for Q3 2025, versus -$9.22 for Q2 2025 and $5.78 for Q1 2025.